Publications
Find research on medicines in development at BioCryst
View publications from medical journals as well as sponsored manuscripts.
Browse our archive of publications
Filter
Showing Publications
-
Oral berotralstat for hereditary angioedema prophylaxis in patients aged 2 to <12 years
Ann Allergy Asthma Immunol
|2025
|Hereditary Angioedema (HAE)
Biocryst
-
Long-term safety and efficacy of once-daily berotralstat in patients with hereditary angioedema
Ann Allergy Asthma Immunol
|2025
|Hereditary Angioedema (HAE)
Biocryst
-
Berotralstat for long-term prophylaxis of hereditary angioedema in Japan: Parts 2 and 3 of the randomized APeX-J Phase III trial
World Allergy Organ J
|2024
|Hereditary Angioedema (HAE)
Biocryst
-
Assessment of HAE prophylaxis transition from androgen therapy to berotralstat: A subset analysis of the APeX-S trial
World Allergy Organ J
|2023
|Hereditary Angioedema (HAE)
Biocryst
-
The Multifactorial Impact of Receiving a Hereditary Angioedema Diagnosis
World Allergy Organ J
|2023
|Hereditary Angioedema (HAE)
Biocryst
-
Hereditary Angioedema Management: Individualization
J Nurse Pract
|2021
|Hereditary Angioedema (HAE)
Biocryst
-
Physician and Patient Perspectives on the Management of Hereditary Angioedema: A Survey on Treatment Burden and Needs
Allergy Asthma Proc
|2021
|Hereditary Angioedema (HAE)
Biocryst
-
Caregivers’ Role in Managing Hereditary Angioedema and Perceptions of Treatment-Related Burdens
Allergy Asthma Proc
|2021
|Hereditary Angioedema (HAE)
Biocryst
-
Patient Perspectives on the Treatment Burden of Injectable Medication for Hereditary Angioedema
Allergy Asthma Proc
|2021
|Hereditary Angioedema (HAE)
Biocryst
-
Insights into the Treatment Burden of Hereditary Angioedema in the Evolving Treatment Landscape
Allergy Asthma Proc
|2021
|Hereditary Angioedema (HAE)
Biocryst
-
Time Trade‑Off Utilities for Hereditary Angioedema Health and Caregiver States
Pharmacoeconomics
|2021
|Hereditary Angioedema (HAE)
Biocryst
-
Hereditary angioedema in children: Review and practical perspective for clinical management
Pediatr Allergy Immunol
|2024
|Hereditary Angioedema (HAE)
Biocryst
-
Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series
Orphanet J Rare Dis
|2024
|Hereditary Angioedema (HAE)
Biocryst
-
Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema
N Engl J Med
|2018
|Hereditary Angioedema (HAE)
Biocryst
-
Letter to the editor: network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema
J Comp Eff Res
|2024
|Hereditary Angioedema (HAE)
Biocryst
-
Berotralstat (BCX7353): Structure-Guided Design of a Potent, Selective, and Oral Plasma Kallikrein Inhibitor to Prevent Attacks of Hereditary Angioedema (HAE)
J Med Chem
|2021
|Hereditary Angioedema (HAE)
Biocryst
-
Hereditary Angioedema Patients Would Prefer Newer-Generation Oral Prophylaxis
J Drug Assess
|2020
|Hereditary Angioedema (HAE)
Biocryst
-
Managing Diagnosis, Treatment and Burden of Disease in Hereditary Angioedema Patients with Normal C1-Esterase Inhibitor
J Asthma Allergy
|2023
|Hereditary Angioedema (HAE)
Biocryst
-
Optimal Management of Hereditary Angioedema: Shared Decision-Making
J Asthma Allergy
|2021
|Hereditary Angioedema (HAE)
Biocryst
-
Meeting Patient Needs in Hereditary Angioedema Care
J Allergy Ther
|2021
|Hereditary Angioedema (HAE)
Biocryst
-
Once-daily oral berotralstat for long-term prophylaxis of hereditary angioedema: The open-label extension of the APeX-2 randomized trial
J Allergy Clin Immunol Pract
|2023
|Hereditary Angioedema (HAE)
Biocryst
-
Specific Targeting of Plasma Kallikrein for Treatment of Hereditary Angioedema: A Revolutionary Decade
J Allergy Clin Immunol Pract
|2021
|Hereditary Angioedema (HAE)
Biocryst
-
Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2)
J Allergy Clin Immunol Pract
|2021
|Hereditary Angioedema (HAE)
Biocryst
-
Oral Once-Daily Berotralstat for the Prevention of Hereditary Angioedema Attacks: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial
J Allergy Clin Immunol
|2020
|Hereditary Angioedema (HAE)
Biocryst
-
Informed Decision-Making in Hereditary Angioedema Prophylaxis
Int Forum Allergy Rhinol
|2021
|Hereditary Angioedema (HAE)
Biocryst
-
The current situation of hereditary angioedema patients in Germany: results of an online survey
Front Med (Lausanne)
|2024
|Hereditary Angioedema (HAE)
Biocryst
-
Patient and Caregiver Perspectives on Oral Transition in the Emerging Hereditary Angioedema Treatment Landscape
Clin Case Rep
|2021
|Hereditary Angioedema (HAE)
Biocryst
-
Population Pharmacokinetic Modeling and Simulations of Berotralstat for Prophylactic Treatment of Attacks of Hereditary Angioedema
Clin Transl Sci
|2022
|Hereditary Angioedema (HAE)
Biocryst
-
Long-Term Safety and Effectiveness of Berotralstat for Hereditary Angioedema: The Open-Label APeX-S Study
Clin Transl Allergy
|2021
|Hereditary Angioedema (HAE)
Biocryst
-
Hereditary angioedema outcomes in US patients switched from injectable long-term prophylactic medication to oral berotralstat
Ann Allergy Asthma Immunol
|2024
|Hereditary Angioedema (HAE)
Biocryst
-
A Case of Normal C1 Esterase Inhibitor Hereditary Angioedema Successfully Treated with Berotralstat
Ann Allergy Asthma Immunol
|2022
|Hereditary Angioedema (HAE)
Biocryst
-
Small Molecule Drugs for Atopic Dermatitis, Rheumatoid Arthritis, and Hereditary Angioedema
Ann Allergy Asthma Immunol
|2021
|Hereditary Angioedema (HAE)
Biocryst
-
Considerations for Transition From Subcutaneous to Oral Prophylaxis in the Treatment of Hereditary Angioedema
Allergy Asthma Clin Immunol
|2021
|Hereditary Angioedema (HAE)
Biocryst
-
Attenuated Androgen Discontinuation in Patients with Hereditary Angioedema: a Commented Case Series
Allergy Asthma Clin Immunol
|2022
|Hereditary Angioedema (HAE)
Biocryst
-
Assessment and Management of Disease Burden and Quality of Life in Patients with Hereditary Angioedema: a Consensus Report
Allergy Asthma Clin Immunol
|2021
|Hereditary Angioedema (HAE)
Biocryst
-
Long-Term Prophylaxis in Hereditary Angioedema Management: Current Practices in France and Unmet Needs
Allergy Asthma Proc
|2022
|Hereditary Angioedema (HAE)
Biocryst
-
Shared Decision-Making in the Management of Hereditary Angioedema: An Analysis of Patient and Physician Perspectives
Allergy Asthma Proc
|2022
|Hereditary Angioedema (HAE)
Biocryst
-
Global Perceptions of the Current and Future Impacts of COVID-19 on Hereditary Angioedema Management
Allergy Asthma Proc
|2022
|Hereditary Angioedema (HAE)
Biocryst
-
Berotralstat (BCX7353) is a Novel, Oral Prophylactic Treatment for Hereditary Angioedema: Review of Phase II and III Studies
Allergy Asthma Proc
|2021
|Hereditary Angioedema (HAE)
Biocryst
-
Androgen Use in Hereditary Angioedema: A Critical Appraisal and Approaches to Transitioning from Androgens to Other Therapies
Allergy Asthma Proc
|2020
|Hereditary Angioedema (HAE)
Biocryst
-
Oral Berotralstat for the Prophylaxis of Hereditary Angioedema Attacks in Patients in Japan: A Phase 3 Randomized Trial
Allergy
|2020
|Hereditary Angioedema (HAE)
Biocryst
-
Expert Consensus on Prophylactic Treatment of Hereditary Angioedema
Allergo J Int
|2022
|Hereditary Angioedema (HAE)
Biocryst
-
Significant response to berotralstat in 3 patients with hereditary angioedema of unknown origin
J Allergy Clin Immunol Pract
|2023
|Hereditary Angioedema (HAE)
Other
-
A Retrospective Analysis of Long-Term Prophylaxis with Berotralstat in Patients with Hereditary Angioedema and Acquired C1-Inhibitor Deficiency-Real-World Data
Clin Rev Allergy Immunol
|2023
|Hereditary Angioedema (HAE)
Other
-
Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians
Front Immunol
|2024
|Hereditary Angioedema (HAE)
Other
-
Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States
Ann Allergy Asthma Immunol
|2020
|Hereditary Angioedema (HAE)
Other
-
Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor: a systematic review of qualitative evidence
Orphanet J Rare Dis
|2020
|Hereditary Angioedema (HAE)
Other
-
Optimal Management of Hereditary Angioedema: Shared Decision-Making
J Asthma Allergy
|2021
|Hereditary Angioedema (HAE)
Other
-
Definition, acronyms, nomenclature, and classification of angioedema: AAAAI, ACAAI, ACARE, and APAACI DANCE consensus
J Allergy Clin Immunol
|2024
|Hereditary Angioedema (HAE)
Other
-
Development and validation of a US quality of life instrument for hereditary angioedema due to C1 inhibitor deficiency
Ann Allergy Asthma Immunol
|2024
|Hereditary Angioedema (HAE)
Other
-
Physician- and patient-reported outcomes by hereditary angioedema type: Data from a real-world study
Allergy Asthma Proc
|2024
|Hereditary Angioedema (HAE)
Other
-
Hereditary angioedema: Epidemiology and burden of disease
Allergy Asthma Proc
|2020
|Hereditary Angioedema (HAE)
Other
-
Severity of hereditary angioedema, prevalence, and diagnostic considerations
Am J Manag Care
|2018
|Hereditary Angioedema (HAE)
Other
-
Hereditary Angioedema
N Engl J Med
|2020
|Hereditary Angioedema (HAE)
Other
-
Consequences of Insurance Coverage Delays and Denials for Patients With Hereditary Angioedema
J Allergy Clin Immunol Pract
|2023
|Hereditary Angioedema (HAE)
Other
-
Prevalence of and risk factors for nutritional deficiency and food allergy in a cohort of 21 patients with Netherton syndrome
Pediatr Allergy Immunol
|2023
|Netherton Syndrome (NS)
Other
-
Human papillomavirus infection in Netherton’s syndrome
Br J Dermatol
|2001
|Netherton Syndrome (NS)
Other
-
The Spectrum of Pathogenic Mutations in SPINK5 in 19 Families with Netherton Syndrome: Implications for Mutation Detection and First Case of Prenatal Diagnosis
J Invest Dermatol
|2001
|Netherton Syndrome (NS)
Other
-
Kallikreins: Essential epidermal messengers for regulation of the skin microenvironment during homeostasis, repair and disease
Matrix Biol Plus
|2020
|Netherton Syndrome (NS)
Other
-
Netherton Syndrome in Children: Management and Future Perspectives
Front Pediatr
|2021
|Netherton Syndrome (NS)
Other
-
Advances in understanding of Netherton syndrome and therapeutic implications
Expert Opin Orphan Drugs
|2020
|Netherton Syndrome (NS)
Other
-
Netherton syndrome; neuropsychological and psychosocial functioning of child and adult patients and their parents
J Health Psychol
|2020
|Netherton Syndrome (NS)
Other
-
Netherton’s Syndrome: A Case of Two Male Siblings Diagnosed in Adulthood
Case Rep Dermatol
|2020
|Netherton Syndrome (NS)
Other
-
An 8-Year-Old Child with Delayed Diagnosis of Netherton Syndrome
Case Rep Pediatr
|2018
|Netherton Syndrome (NS)
Other
-
Netherton syndrome and papillomatous lesions—Should we perform human papilloma virus vaccination?
J Eur Acad Dermatol Venereol
|2024
|Netherton Syndrome (NS)
Other
-
Comel-Netherton syndrome: A local skin barrier defect in the absence of an underlying systemic immunodeficiency
Allergy
|2020
|Netherton Syndrome (NS)
Other
-
Characteristics of children with Netherton syndrome: a review of 21 patients
J Eur Acad Dermatol Venereol
|2021
|Netherton Syndrome (NS)
Other
-
The challenging management of a series of 43 infants with Netherton syndrome: unexpected complications and novel mutations
Br J Dermatol
|2021
|Netherton Syndrome (NS)
Other
-
Netherton Syndrome: A Genotype-Phenotype Review
Mol Diagn Ther
|2017
|Netherton Syndrome (NS)
Other
-
Discovery of highly potent small molecule kallikrein inhibitors
Mol Immunol
|2007
|Diabetic Macular Edema (DME)
Other
-
The suprachoroidal pathway: a new drug delivery route to the back of the eye
Drug Discov Today
|2015
|Diabetic Macular Edema (DME)
Other
-
Microinjection via the suprachoroidal space: a review of a novel mode of administration
Am J Manag Care
|2022
|Diabetic Macular Edema (DME)
Other
-
Plasma Kallikrein-Kinin System as a VEGF-Independent Mediator of Diabetic Macular Edema
Diabetes
|2015
|Diabetic Macular Edema (DME)
Other
-
Characterization of the Vitreous Proteome in Diabetes without Diabetic Retinopathy and Diabetes with Proliferative Diabetic Retinopathy
J Proteome Res
|2008
|Diabetic Macular Edema (DME)
Other
-
Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation
Nat Med
|2007
|Diabetic Macular Edema (DME)
Other
-
The Role of Plasma Kallikrein–Kinin Pathway in the Development of Diabetic Retinopathy: Pathophysiology and Therapeutic Approaches
Semin Ophthalmol
|2016
|Diabetic Macular Edema (DME)
Other
-
Kinins and Their Receptors as Potential Therapeutic Targets in Retinal Pathologies
Cells
|2021
|Diabetic Macular Edema (DME)
Other
-
Plasma Kallikrein Mediates Vascular Endothelial Growth Factor-Induced Retinal Dysfunction and Thickening
Invest Ophthalmol Vis Sci
|2016
|Diabetic Macular Edema (DME)
Other
-
Molecules related to diabetic retinopathy in the vitreous and involved pathways
Int J Ophthalmol
|2022
|Diabetic Macular Edema (DME)
Other
-
Plasma kallikrein-kinin system and diabetic retinopathy
Biol Chem
|2013
|Diabetic Macular Edema (DME)
Other
-
The evolving therapeutic landscape of diabetic retinopathy
Expert Opin Biol Ther
|2023
|Diabetic Macular Edema (DME)
Other
-
Mechanisms of macular edema
Front Med (Lausanne)
|2023
|Diabetic Macular Edema (DME)
Other
-
Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications
Cells
|2022
|Diabetic Macular Edema (DME)
Other
-
Mechanisms of macular edema: Beyond the surface
Prog Retin Eye Res
|2018
|Diabetic Macular Edema (DME)
Other
-
Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory
J Diabetes Res
|2016
|Diabetic Macular Edema (DME)
Other
-
Clinical Experience with Berotralstat in Patients with Hereditary Angioedema with Normal C1-Esterase Inhibitor: A Commented Case Series
J Asthma Allergy
|2024
|Hereditary Angioedema (HAE)
Biocryst